A Randomized Controlled Trial Comparing Alloderm-RTU with DermACELL in Immediate Subpectoral Implant-Based Breast Reconstruction.
Angel ArnaoutJing ZhangSimon FrankMoein MomtaziErin CordeiroAmanda RobertsAmmara GhummanDean FergussonCarol StoberGregory PondAhwon JeongLisa VandermeerBrian HuttonMark Clemonsnull On Behalf Of The REaCT InvestigatorsPublished in: Current oncology (Toronto, Ont.) (2020)
This is the first prospective randomized clinical trial comparing the two most commonly used human-derived ADMs. There was no statistically significant difference in drain duration, minor, or major complications between DermACELL over Alloderm-RTU in immediate subpectoral permanent implant-based breast reconstruction post-mastectomy.